Get In Touch
  • Fb-icon
  • Top-linkdin
  • Top-twitter
  • Rss
img
Current Issue
section
logo

animation-neutral-tts-300x100' width='300' height='100' border='0

Waters and BioInfra Establish ASEAN Academy for Bioanalysis

By Anvita Pillai, @Anvitap21,

Added 21 June 2022

The training academy will help enhance regional scientific competitiveness and the quality of pharmaceutical research and testing

Waters Corporation has collaborated with BioInfra, a pioneering contract research organisation (CRO) company for the pharmaceutical and clinical fields, to establish the ASEAN Academy for Bioanalysis jointly. The academy is dedicated to providing scientists with the hands-on knowledge required to design and perform a variety of bioanalytical methods, which are vital throughout every stage of drug discovery and development.

“There is a growing need for contract research organisations (CROs), pharmaceutical companies and regulators in the region to have access to the bioanalysis training needed to conduct drug equivalence tests for the approval of generic drugs,” said David Curtin, Waters Vice President of Asia Pacific. “Our vision is that the training provided at the ASEAN Academy will help grow generic drug manufacturing in the region, and in turn, help provides lower-cost prescription drug options for the people of Southeast Asia.”

Located at the BioInfra headquarters in Seoul, the ASEAN Academy for Bioanalysis will offer hands-on training using Waters's latest analytical instruments and software. Trainees will focus on the bioanalytical aspect of bioequivalence trials to ensure they are conducted according to the applicable principles of Good Laboratory Practice (GLP).

Bioanalytical methods used today require samples to be well-characterised, fully validated, and documented to yield reliable results that can be satisfactorily interpreted. These skills will help enhance the regional scientific competitiveness and the quality of pharmaceutical research and testing needed to meet the region’s growing demands for access to clinical trials and generic drugs fueled by rising elderly populations facing acute and chronic illnesses.

“We are thrilled to partner with Waters Corporation on the establishment of the ASEAN Academy for Bioanalysis," said Sang Deuk Lee, CEO of BioInfra. “By providing the scientific community of Southeast Asia with a much-needed resource for bioanalytical training, we are further supporting BioInfra’s mission to create a healthy future for all people, regardless of their age or economic status.”

comments powered by Disqus